Last reviewed · How we verify
HIDAC (high dose cytarabine)
High-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to cell death in rapidly dividing cells.
High-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to cell death in rapidly dividing cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Non-Hodgkin lymphoma.
At a glance
| Generic name | HIDAC (high dose cytarabine) |
|---|---|
| Sponsor | Pfizer |
| Drug class | Nucleoside analog; antimetabolite |
| Target | DNA polymerase; thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cytarabine is a cytidine analog that is phosphorylated intracellularly and incorporated into DNA, causing chain termination and inhibition of DNA polymerase. At high doses, it achieves greater intracellular accumulation and DNA incorporation, resulting in enhanced cytotoxic effects against leukemic and lymphoma cells. The drug is particularly effective in hematologic malignancies due to the high proliferation rate of these cells.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Neurotoxicity (cerebellar syndrome, encephalopathy)
- Mucositis
- Nausea and vomiting
- Hepatotoxicity
- Infection
Key clinical trials
- A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias (PHASE1)
- Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML (PHASE2)
- Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (PHASE1)
- Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance (PHASE2)
- Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission (PHASE2)
- High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML (PHASE2)
- Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma (PHASE2)
- Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIDAC (high dose cytarabine) CI brief — competitive landscape report
- HIDAC (high dose cytarabine) updates RSS · CI watch RSS
- Pfizer portfolio CI